Cocaine detoxification by human plasma butyrylcholinesterase

Toxicology and Applied Pharmacology

Volumn 145, Issue 2, 1997, Pages 363-371

  Lynch, Thomas J ^a,d   Mattes, Carol E ^a,b   Singh, Anu ^b   Bradley, Roy M ^a   Brady, Roscoe O ^c   Dretchen, Kenneth L ^b  

^a Pharmavene Inc   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c US Food and Drug Administration ^*  (United States)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE; COCAINE;

ANIMAL EXPERIMENT; ARTICLE; DRUG DETOXIFICATION; DRUG TOXICITY; ENZYME ACTIVITY; ENZYME THERAPY; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; RAT; SEIZURE; SURVIVAL RATE;

ANIMALIA;

EID: 0031213567     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1997.8187     Document Type: Article

References (74)

1. Allen R. S., Hunter J. Detection of hydrolases with naphthol esters as substrates. J. Histochem. Cytochem. 8:1960;50-57.
2. Ambre J., Ruo T., Nelson J., Belknap S. Urinary excretion of cocaine, benzoylecgonine and ecgonine methyl ester in humans. J. Anal. Toxicol. 12:1988;301-306.
3. Ambre J., Ruo T., Smith G. L., Backes D., Smith C. M. Ecgonine methyl ester, a major metabolite of cocaine. J. Anal. Toxicol. 6:1982;26-29.
4. Ambre J. J. Cocaine kinetics in humans. Cocaine, Marijuana, Designer Drugs: Chemistry, Pharmacology and Behavior. 1987;CRC Press, Boca Raton. p. 53-69.
5. Arpagaus M., Katt M., Vatsis K. P., Bartels C. F., LaDu B. N., Lockridge O. Structure of the gene for human butyrylcholinesterase. Evidence for a single copy. Biochemistry. 29:1990;124-131.
6. Bauld H. W., Gibson P. F., Jebson P. J., Brown S. S. Aetiology of prolonged apnoea after suxamethonium. Brit. J. Anaesth. 46:1974;273-278.
7. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
8. Brogan W. C., Lange R. A., Glaumann D. B., Hillis L. D. Recurrent coronary vasoconstriction caused by intranasal cocaine: Possible role for metabolites. Ann. Intern. Med. 116:1992;556-561.
9. Chatonnet A., Lockridge O. Comparison of butyrylcholinesterase and acetylcholinesterase. Biochem. J. 260:1989;625-634.
10. Cohn E. J., Strong L. E., Hughes W. L., Mulford D. J., Ashworth J. N., Melin M., Taylor H. L. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions the protein and lipoprotein components of biological tissues and fluids. J. Am. Chem. Soc. 68:1946;459-475.
11. Cygler M., Schrag J. D., Sussman J. L., Harel M., Silman I., Gentry M., Doctor B. P. Relationship between sequence conservation and three-dimensional structure in a large family of esterases, lipases and related proteins. Protein Sci. 2:1993;366-382.
12. Das P. K., Liddell J. Purification and properties of human serum cholinesterase. Biochem. J. 116:1970;875-881.
13. Davis B. J. Disc electrophoresis II: Method and application to human serum proteins. Ann. NY Acad. Sci. 121:1964;404-427.
14. Deitz A. A., Rubinstein H. M., Lubrano T. Colorimetric determination of serum cholinesterase and its genetic variants by the propionylthiocholine-dithiobis(nitrobenzoic acid procedure. Clin. Chem. 19:1973;1309-1313.
15. Delbruck A., Henkel E. A rare genetically determined variant of pseudocholinesterase in two German families with high plasma enzyme activity. Eur. J. Biochem. 99:1979;65-69.
16. Devenyi P. Cocaine complications and pseudocholinesterase. Ann. Intern. Med. 110:1989;167-168.
17. Ellman G. L., Courtney K. D., Andres V., Featherstone F. M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7:1961;88-95.
18. Evans R. T., Wardell J. On the identification and frequency of the J and K cholinesterase phenotypes in a caucasian population. J. Med. Genet. 21:1984;99-102.
19. Gatley S. J. Activities of the enantiomers of cocaine and some related compounds as substrates and inhibitors of plasma butyrylcholinesterase. Biochem. Pharmacol. 41:1991;1249-1254.
20. Goedde H. W., Altland K., Scholler K. L. Pharmakogenetische reaktion auf succinyldicholin: Therapie der verlangerten apnoe. Med. Klin. 62:1967;1631-1635.
21. Harris H., Whittaker M. Differential inhibition of serum cholinesterase with fluoride: Recognition of two new phenotypes. Nature (London). 191:1961;496-498.
22. Hoffman R. S., Henry G. C., Howland M. A., Weisman R. S., Weil L., Goldfrank L. R. Association between life-threatening cocaine toxicity and plasma cholinesterase activity. Ann. Emer. Med. 21:1992a;247-253.
23. Hoffman R. S., Henry G. C., Wax P. M., Weisman R. S., Howland M. A., Goldfrank L. R. Decreased plasma cholinesterase activity enhances cocaine toxicity in mice. J. Pharmacol. Exp. Ther. 263:1992b;698-702.
24. Hollander J. E. The management of cocaine-associated myocardial ischemia. N. Engl. J. Med. 333:1995;1267-1272.
25. Inaba T., Stewart D. J., Kalow W. Metabolism of cocaine in man. Clin. Pharmacol. Ther. 23:1978;547-552.
26. Isenschmid D. S., Levine B. S., Caplan Y. H. A comprehensive study of the stability of cocaine and its metabolites. J. Anal. Toxicol. 13:1989;250-256.
27. Jatlow P. Cocaine: Analysis, pharmacokinetics and metabolic disposition. Yale J. Biol. Med. 61:1988;105-113.
28. Jatlow P., Barash P. G., Van Dyke C., Radding J., Byck R. Cocaine and succinylcholine: A new caution. Anesth. Analg. 58:1979;235-238.
29. Kalow W., Genest K. A. A method for the detection of atypical forms of human serum cholinesterase: Determination of dibucaine numbers. Can. J. Biochem. 35:1957;339-346.
30. Kalow W., Lindsay H. A. A comparison of optical and manometric methods for the assay of human serum cholinesterase. Can. J. Biochem. 33:1955;568-574.
31. Kambam J. R., Naukam R., Berman M. L. Inhibition of pseudocholinesterase activity protects from cocaine-induced cardiorespiratory toxicity in rats. J. Lab. Clin. Med. 119:1992;553-556.
32. Kambam J. R., Mets B., Hickman R., Janicki P., James M. F., Kirsch R. The effects of inhibition of plasma cholinesterase activity on systemic toxicity and blood catecholamine levels from cocaine infusion in pigs. J. Lab. Clin. Med. 122:1993;188-196.
33. Konkol R. J., Erickson B. A., Doerr J. K., Hoffman R. G., Madden J. A. Seizures induced by the cocaine metabolite benzoylecgonine in rats. Epilepsia. 33:1992;420-427.
34. Krause A., Lane A. B., Jenkins T. A new high activity plasma cholinesterase variant. J. Med. Genet. 25:1988;677-681.
35. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London). 227:1970;680-685.
36. Landry D. W., Zhao K., Yang G. X.-Q., Glickman M., Georgiadis T. M. Antibody-catalyzed degradation of cocaine. Science. 259:1993;1899-1901.
37. Liddell J., Lehmann H., Silk E. A. A "silent" pseudocholinesterase gene. Nature (London). 193:1962;561-562.
38. Lockridge O. Structure of human serum cholinesterase. BioEssays. 9:1988;125-128.
39. Lockridge O., Bartels C. F., Vaughan T. A., Wong C. W., Norton S. E., Johnson L. L. Complete amino acid sequence of human serum cholinesterase. J. Biol. Chem. 262:1987;549-557.
40. Lockridge O., Eckerson H. W., La Du B. N. Interchain disulfide bonds and subunit organization in human serum cholinesterase. J. Biol. Chem. 254:1979;8324-8330.
41. Lockridge O., La Du B. N. Comparison of atypical and usual human serum cholinesterase. J. Biol. Chem. 253:1978;361-366.
42. Lockridge O., La Du B. N. Loss of the interchain disulfide peptide and dissociation of the tetramer following limited proteolysis of native human serum cholinesterase. J. Biol. Chem. 257:1982;12012-12018.
43. Madden J. A., Powers R. H. Effect of intraluminally infused cocaine and metabolites on cat cerebral arteriesin vitro. Life Sci. 47:1990;1109-1114.
44. Main A. R., Soucie W. G., Buxton I. L., Arinc E. The purification of cholinesterase from horse serum. Biochem. J. 143:1974;733-744.
45. Marzuk P. M., Tardiff K., Leon A. C., Hirsch C. S., Stajic M., Potera L., Hartwell N., Iqbal I. Fatal injuries after cocaine use as a leading cause of death among young adults in New York. N. Engl. J. Med. 332:1995;1753-1757.
46. Matsubara K., Kagawa M., Fukui Y. In vivoin vitro. Forensic Sci. Int. 26:1984;169-180.
47. Mattes C., Bradley R., Slaughter E., Browne S. Cocaine and butyrylcholinesterase (BChE): Determination of enzymatic parameters. Life Sci. 58:1996;257-261.
48. Mattes C. E., Lynch T. J., Singh A., Bradley R. M., Kellaris P. A., Brady R. O., Dretchen K. L. Therapeutic use of butyrylcholinesterase for cocaine intoxication. Toxicol. Appl. Pharmacol. 145:1997;372-380.
49. McComb R. B., LaMotta R. V., Wetstone H. J. Procedure for the detecting atypical serum cholinesterase using nitrophenyl butyrate as substrate. Clin. Chem. 11:1965;645-652.
50. McGuire M. C., Magueira C. P., Bartels C. F., Lightstone H., Hajra A., Van der Spek A. F., Lockridge O., LaDu B. N. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. Proc. Natl. Acad. Sci. USA. 86:1989;953-957.
51. Merigan K. S., Park L. J., Leeper K. V., Browning R. G., Giometi R. Adrenergic crisis from crack cocaine injection: Report of five cases. J. Emer. Med. 12:1994;485-490.
52. Millard C. B., Broomfield C. A. A computer model of glycosylated human butyrylcholinesterase. Biochem. Biophys. Res. Commun. 189:1992;1280-1286.
53. 3. J. Pharm. Pharmacol. 27:1975;784-786.
54. Muensch H., Goedde H., Yoshida A. Human-serum cholinesterase subunits and number of active sites of the major component. Eur. J. Biochem. 70:1976;217-223.
55. Naguib M., Daoud W., El-Gammal M., Ammar A., Turkistani A., Selim M., Altamimi W., Sohaibani M. O. Enzymatic antagonism of mivacurium-induced neuromuscular blockade by human plasma cholinesterase. Anesthesiology. 83:1995;694-701.
56. Nelson L., Hoffman R. S. How to manage acute MI when cocaine is the cause. J. Crit. Med. 10:1995;39-43.
57. Neville L. F., Gnatt A., Lowenstein Y., Seidman S., Ehrlich G., Soreq H. Intramolecular relationships in cholinesterases revealed by oocyte expression of site-directed and natural variants of human BCHE. EMBO J. 11:1992;1641-1649.
58. Om A., Ellahham S., Ornato J. P., Picone C., Theogaraj J., Corretjer G. P., Vetrovec G. W. Medical complications of cocaine: Possible relationship to low plasma cholinesterase enzyme. Am. Heart J. 125:1993;1114-1117.
59. Ostergaard D., Viby-Mogensen J., Hanel H. K., Skovgaard L. T. Half-life of plasma cholinesterase. Acta Anesth. Scand. 32:1988;266-269.
60. Ostergaard D., Jensen F. S., Viby-Mogensen J. Reversal of intense mivacurium block with human plasma cholinesterase in patients with atypical plasma cholinesterase. Anesthesiology. 82:1995;1295-1298.
61. Prody C. A., Zevin-Sonkin D., Gnatt A., Goldberg O., Soreq H. Isolation and characterization of full-length cDNA clones coding for cholinesterase from fetal human tissues. Proc. Natl. Acad. Sci. USA. 84:1987;3555-3559.
62. Raveh L., Grunwald J., Marcus D., Papier Y., Cohen E., Ashani Y. Human butyrylcholinesterase as a general prophylactic antidote for nerve agent toxicity. Biochem. Pharmacol. 45:1993;2465-2472.
63. Scholler K. L., Goedde H. W., Benkman H. G. The use of serum cholinesterase in succinylcholine apnoea. Can. Anaesth. Soc. J. 24:1977;396-400.
64. K. S. Shrank, 1992, Cocaine-related emergency department presentations, Acute Cocaine Intoxification: Current Methods of Treatment, H. Sorer, 20, 43, NIDA Research Monograph 123, Rockville, MD.
65. Soreq H., Seidman S., Dreyfus P. A., Zevin-Sonkin D., Zakat H. Expression and tissue-specific assembly of human butyrylcholine esterase in microinjectedXenopus laevis. J. Biol. Chem. 264:1989;10608-10613.
66. Stewart D. J., Inaba T., Lucassen M., Kalow W. Cocaine metabolism: Cocaine and norcocaine hydrolysis by liver and serum esterases. Clin. Pharmacol. Ther. 25:1979;464-468.
67. Stewart D. J., Inaba T., Tang B. K., Kalow W. Hydrolysis of cocaine in human plasma by cholinesterase. Life Sci. 20:1977;1557-1564.
68. Stoscheck C. M. Quantitation of protein. Methods Enzymol. 182:1990;50-62.
69. Surgenor D. M., Ellis D. Preparation and properties of serum and plasma proteins. Plasma cholinesterase. J. Am. Chem. Soc. 76:1954;6049-6051.
70. Sussman J. S., Harle M., Forlov F., Oefner C., Goldman A., Toker L., Silman I. Atomic structure of acetylcholinesterase fromTorpedo californica: Science. 253:1991;872-879.
71. Vellom D. C., Radic Z., Li Y., Pickering N. A., Camp S., Taylor P. Amino acid residues controlling acetylcholinesterase and butyrylcholinesterase specificity. Biochemistry. 32:1993;12-17.
72. Vitti T. G., Boni R. L. Metabolism of cocaine. Barnett G., Chiang C. N. Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs. 1985;427-440 Biomedical Publications, Foster City.
73. Whittaker M. Cholinesterase. Monographs in Human Genetics, Vol. 11. 1986;Karger, Basel.
74. Yoshida A., Motulsky A. G. A pseudocholinesterase variant (E Cynthiana) associated with elevated plasma enzyme activity. Am. J. Hum. Genet. 21:1969;486-498.